John Kiely sold $143k of AMRX
director at Amneal Pharmaceuticals, Inc.. 17,058 shares at an average of $8.38, traded Nov 22, 2024, filed Nov 26, 2024.
Score components
- +15RoleDirector
- +11Trade size$143k at market
- 0Share of holdings soldSold 6.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-049297, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | MOption exercise Class A Common Stock | +28,506 | $4.76 | $136k | 284,233 | Nov 26, 2024 |
| Nov 22, 2024 | SOpen-market sale Class A Common Stock | -17,058 | $8.38 | $143k | 267,175 | Nov 26, 2024 |
| Nov 22, 2024 | MOption exercise Stock Optionderivative | -28,506 | $0.00 | $0 | 0 | Nov 26, 2024 |
Related signals
Other insiders at Amneal Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $761k 94,906 shares | -6% | |
| 32Weak | AMRXsell Amneal Pharmaceuticals, Inc. | Gautam Patel director | $453k 56,426 shares | -3% | |
| 50Moderate | Amneal Pharmaceuticals, Inc. | Nikita Shah Executive Vice President | $372k 49,140 shares | -11% | |
| 51Moderate | Amneal Pharmaceuticals, Inc. | John Kiely director | $380k 50,000 shares | -16% | |
| 18Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $69k 8,668 shares | -1% | |
| 15Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $664k 80,000 shares | -4% | |
| 52Moderate | Amneal Pharmaceuticals, Inc. | Tushar Bhikhubhai Patel owner | $42M 5,000,000 shares | -9% | |
| 61Notable | Amneal Pharmaceuticals, Inc. | Emily Peterson Alva director | $712k 80,000 shares | -32% | |
| 65Notable | Amneal Pharmaceuticals, Inc. | Tasos Konidaris Executive Vice President & CFO | $891k 100,000 shares | -14% | |
| 72Notable | Amneal Pharmaceuticals, Inc. | Jason B. Daly EVP, Chief Legal Officer | $792k 90,000 shares | -73% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.